Most Recent Articles by Steve Duffy
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Patients who received concomitant NeP medications showed little difference in therapeutic response in comparison to those who received pregabalin alone.
The researchers graded their findings A, B, or C based on study quality.
The 6 mg dose will remain available.
Treatment with risperidone over a 6 month period was associated with an average weight gain of 5.4±3.4kg.
More Articles by Steve Duffy
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- In Stroke, No Clear Benefit for Head Positioning